n/a
Abstract Title:

Enhanced Glioblastoma Selectivity of Harmine via the Albumin Carrier.

Abstract Source:

J Biomed Nanotechnol. 2022 Apr 1 ;18(4):1052-1063. PMID: 35854453

Abstract Author(s):

Shi-Hui Liu, Qing-Zhen Wang, Tao Liu, Ru Bai, Man-Man Ma, Qiao-Lin Liu, Hui-Ge Zhou, Jing Liu, Mei Wang

Article Affiliation:

Shi-Hui Liu

Abstract:

Glioblastoma, the most common tumor in the brain, has witnessed very little clinical progress over the last decades. Exploring and discovering new therapeutic strategies for glioblastoma has become a critical problem. Harmine (HM), belonging to the beta-carboline alkaloid, is a natural product and isolated from the seeds ofL., which own notable antitumor activity. However, the poor water solubility and less selectivity of HM severely limit its clinical use. For enhancing its selective ability to tumor cells, we fabricated a kind of protein nanoparticles (BSA-HM NPs), composed of the modified bovine serum albumin (BSA) and HM. It was substantiated throughandexperiment that BSA-HM NPs could predominantly accumulate in tumor tissues and exhibited remarkably enhanced antitumor efficacy. This study provides a promising strategy to improve the bioavailability and avoid side effects of HM as antitumor agents by choosing BSA as carriers.

Study Type : In Vitro Study
Additional Links

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.